Clinical Trials Logo

Genito Urinary Cancer clinical trials

View clinical trials related to Genito Urinary Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT06028152 Completed - Breast Cancer Clinical Trials

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning

Start date: October 31, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with breast, lung, and/or genito-urinary cancers treated at Penn State Cancer Institute and their loved ones perform advance care planning. The main questions it aims to answer are: - What modifications and/or adaptations are necessary to Hello for use in cancer populations? - How do different delivery models compare for recruitment in terms of feasibility and efficiency? Participants will: - Complete pre-game questionnaires - Play the Hello game - Complete post-game questionnaires - Participate in a focus group

NCT ID: NCT04578132 Active, not recruiting - Covid19 Clinical Trials

Description of the Population With Genitourinary Tumors and COVID-19

SOGUGCOVID
Start date: November 24, 2020
Phase:
Study type: Observational

The identification of patients with genitourinary tumors who suffer from the infection by the Serious Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2) virus can represent multiple benefits both for themselves and for health professionals and the health system itself. We would be able to know more precisely the clinical evolution of these type of patient, to know their prognosis and being capable to select the most appropriate treatment modality for future pandemics. SOGUG-COVID is an observational prospective-retrospective trial purely epidemiological, that aims to describe the population with genitourinary tumors (urothelial cancer, prostate cancer, testicular cancer and kidney cancer) infected by COrona VIrus Disease 19 (COVID-19) treated in Spanish hospitals, learn about the clinical presentation, therapeutic evolution and prognosis of said intercurrent infectious process, as well as its possible relationship with different clinical and therapeutic factors.

NCT ID: NCT03134027 Suspended - Prostate Cancer Clinical Trials

Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers

Immune PDX
Start date: October 19, 2017
Phase:
Study type: Observational

The objective of this study is to obtain human blood CD34+ hematopoietic stem/progenitor cells (HSPCs) to reconstitute a match human immune system in our PDX model. The hypothesis is that by using matched leukocytes and PDX from the same patient, rejection of the PDX by the host immune system will not be observed and therefore a preclinical model to study immunotherapy can be developed to study, understand and improve upon our current therapies. HSPCs will be collected from bone marrow aspirate obtained from a bone marrow biopsy. The secondary objective is to use patient tumor biopsy samples or circulating tumor cell samples to develop additional preclinical models of GU cancers, particularly prostate cancer, that are clinically relevant by generating additional PDXs.